Linezolid IV/PO for the Treatment of Vancomycin-Resistant Enterococcus Infections in Children

Date de début de l'étude : 1 février 2002

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: * Hospitalized/chronic care pediatric patients (birth through 17 years) * Known infections due to vancomycin-resistant enterococcus species, including diagnosis of hospital-acquired pneumonia, complicated skin and skin structure infections, catheter-related bacteremia, bacteremia of unidentified source, and other infections * Requires a minimum of 3 days of IV medication * Patients with mixed infections due to VRE \& gram negative bacteria are allowed to enroll in the study. For most of the infections, 2 or more of additional symptoms are required. Exclusion Criteria: * Potentially effective concomitant antibiotic * A high surgical cure rate * Medical conditions which would preclude clinical evaluation or require treatment of longer duration than 28 days * 24 hours of antibiotic treatment within 48 hours of study entry (unless pre-approved) * Having an infected device that could not be removed